Cost‐effectiveness analysis of sintilimab plus <scp>IBI305</scp> versus sorafenib for unresectable hepatic cell carcinoma in China

Zhe Xu, Zhuomiao Ye, Yu‐kai Tang, Dongfeng Deng, Qin Zhou, Man Fang, Ying‐ying Zhang, Xiang‐Ping LiCancer 2023 · DOI

TL;DR

This study evaluates the cost-effectiveness of a new cancer treatment, sintilimab plus IBI305, compared to the current standard, sorafenib, for unresectable liver cancer in China. The analysis concludes that, even with potential insurance coverage, the new treatment is unlikely to be cost-effective due to its high price, suggesting a need for price reductions to make it accessible.

What Problem Does This Paper Address?

Liver cancer, particularly hepatocellular carcinoma (HCC), is a significant health burden globally, with advanced stages often being unresectable. While traditional treatments have limited efficacy, targeted therapies like tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) have emerged as promising options. Sintilimab, an ICI, combined with IBI305 (a bevacizumab biosimilar), has shown clinical benefits in first-line treatment for unresectable HCC, potentially offering better outcomes than sorafenib. However, the economic viability of this new combination therapy in the Chinese healthcare system remains unclear. This paper aims to fill that gap by conducting a cost-effectiveness analysis from the perspective of Chinese payers, considering drug pricing and insurance coverage.

Methods

The researchers employed a Markov model to simulate the progression of HCC patients over time. This model divides patient health into distinct states: stable disease (SD), progressive disease (PD), and death. Patients begin in the SD state and can transition between states based on probabilities derived from clinical trial data. For second-line treatment after disease progression, the model assumes patients receive regorafenib, as per Chinese clinical guidelines.

Key aspects of the methodology include:

  • Data Source: Primarily the ORIENT-32 clinical trial, which compared sintilimab plus IBI305 against sorafenib in patients with unresectable HCC.
  • Time Horizon: A 10-year simulation period was used to capture the long-term effects of the treatments.
  • Perspective: The analysis was conducted from the Chinese payer's perspective, incorporating local drug prices and insurance policies.
  • Cost and Utility Estimation: Direct medical costs (medication, follow-up, laboratory tests, adverse events) and health utility scores (representing quality of life in different health states) were estimated. Utility values for SD and PD states were sourced from previous HCC studies.
  • Statistical Analysis:
    • Parametric survival models were used to estimate transition probabilities between health states, fitting data from Kaplan-Meier curves.
  • Incremental Cost-Effectiveness Ratio (ICER) was the primary metric to evaluate cost-effectiveness.
  • Sensitivity analyses (one-way and probabilistic) were performed to assess the impact of uncertainty in model parameters on the results.
  • A willingness-to-pay (WTP) threshold of three times China's GDP per capita in 2021 ($38,334) was used as a benchmark for cost-effectiveness.

Datasets

  • ORIENT-32 Clinical Trial Data: This multi-center, randomized controlled trial provided the primary dataset for patient characteristics, treatment outcomes (survival, progression), and adverse events for both the sintilimab + IBI305 group and the sorafenib group.
  • Chinese National Basic Medical Insurance (CNBMI) Drug Catalog: Used to obtain drug prices and understand coverage policies for sintilimab and sorafenib.
  • Local Hospital Sales Prices and Drug Supplier Consultations: Supplemented drug pricing information.
  • Previously Published HCC-Related Studies: Provided health utility values for stable disease (SD) and progressive disease (PD) states, as these were not publicly available from the ORIENT-32 trial.

Key Insights and Ideas

  • High Cost is the Primary Barrier: The most striking insight is that despite potential clinical benefits, the high price of sintilimab plus IBI305 is the main driver preventing it from being cost-effective in China.
  • Sensitivity to Cost and Utility: The analysis revealed that the ICER is highly sensitive to the total cost of the sintilimab plus IBI305 regimen and the health utility values associated with stable and progressive disease. This highlights the critical role of drug pricing and patient quality of life in economic evaluations.
  • Insurance Coverage Modest Impact: While Medicare reimbursement for both drugs was considered, it only slightly reduced the ICER, indicating that even with coverage, the cost remains a significant issue.
  • Need for Price Reduction: The study explicitly states that the total cost of sintilimab plus IBI305 would need to be reduced by at least 31.9% to be considered cost-effective by Chinese payers.
  • Comparison to Other Therapies: The paper positions this analysis within the broader context of HCC treatment, noting that other advanced therapies like atezolizumab plus bevacizumab have also been found to be not cost-effective in China, suggesting a systemic challenge with novel combination therapies.

Key Results

  • Base-Case Analysis (Without Medicare): Sintilimab plus IBI305 generated an additional $17,552.17 in costs and 0.33 quality-adjusted life years (QALYs) compared to sorafenib, resulting in an ICER of $52,817.89 per QALY. This ICER is significantly higher than the WTP threshold of $38,334.
  • Base-Case Analysis (With Medicare): The ICER increased slightly to $54,393.97 per QALY, remaining above the WTP threshold.
  • Sensitivity Analysis: The cost of sintilimab plus IBI305 was identified as the most influential factor on the ICER.
  • Probabilistic Sensitivity Analysis (PSA): Showed a very low probability (1.28%) of sintilimab plus IBI305 being cost-effective at the WTP threshold of $38,334.

Limitations and Future Work

The authors acknowledge several limitations:

  • Generalizability of Trial Data: Clinical trial participants may adhere to treatment more strictly than real-world patients, potentially overestimating treatment effectiveness.
  • Short Follow-up Period: The ORIENT-32 trial's follow-up was relatively short, and the median overall survival for the sintilimab plus IBI305 group was not reached. Long-term efficacy data are needed.
  • Utility Value Uncertainty: Health utility values were derived from previous studies and may not perfectly reflect the actual quality of life for HCC patients in China.
  • Subsequent Treatment Bias: Differences in subsequent treatment choices between the groups in the ORIENT-32 trial (e.g., more patients in the sorafenib group receiving ICIs) could have influenced the observed efficacy.

Future work should focus on:

  • Updating Efficacy Data: Incorporating longer-term follow-up data from clinical trials.
  • Real-World Data: Conducting analyses using real-world patient data to assess treatment effectiveness and costs in routine clinical practice.
  • Price Negotiations: Further research into the impact of price reductions and negotiations on the cost-effectiveness of sintilimab plus IBI305.
  • Broader Patient Populations: Investigating cost-effectiveness in different subgroups of HCC patients.

Summary updated

Abstract

Regardless of whether the price of sintilimab plus IBI305 and sorafenib is covered by Medicare, sintilimab plus IBI305 is unlikely to be cost-effective for first-line treatment of patients with unresectable HCC.
BibTeX
@inproceedings{xu2023costeffectiveness,
  author = {Zhe Xu and Zhuomiao Ye and Yu‐kai Tang and Dongfeng Deng and Qin Zhou and Man Fang and Ying‐ying Zhang and Xiang‐Ping Li},
  title = {{Cost‐effectiveness analysis of sintilimab plus <scp>IBI305</scp> versus sorafenib for unresectable hepatic cell carcinoma in China}},
  booktitle = {Cancer},
  year = {2023},
  doi = {10.1002/cam4.5724},
}
Figure